Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 10, pp 1421–1428

Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP

  • Takeshi Hara
  • Hisashi Tsurumi
  • Naoe Goto
  • Nobuhiro Kanemura
  • Takeshi Yoshikawa
  • Senji Kasahara
  • Toshiki Yamada
  • Michio Sawada
  • Hideko Goto
  • Kenji Fukuno
  • Jun-ichi Kitagawa
  • Ichiro Yasuda
  • Naoki Katsumura
  • Masao Takemura
  • Takeshi Takahashi
  • Tsuyoshi Takami
  • Hisataka Moriwaki
Original Paper

DOI: 10.1007/s00432-009-0586-4

Cite this article as:
Hara, T., Tsurumi, H., Goto, N. et al. J Cancer Res Clin Oncol (2009) 135: 1421. doi:10.1007/s00432-009-0586-4

Abstract

Introduction

We previously reported that serum concentrations of soluble Fas (sFas) predict the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) after treatment with CHOP but without rituximab (R). Here, we investigated whether the role of sFas as a prognostic factor remains valid in the R-CHOP era.

Patients

We treated 132 patients with DLBCL between October 1995 and September 2002 (group A: without rituximab), and 75 between December 2002 and March 2007 (group B: with rituximab). The patients received eight cycles of CHOP or THP (tetrahydropyranyl-adriamycin)-COP before September 2002, and R-CHOP or R-THP-COP after October 2002. The distribution of patients according to the International Prognostic Index did not significantly differ between the groups.

Results

The 5-year overall survival (OS) rates for patients with sFas levels of ≥3.0 and <3.0 ng/ml in group A were 19.8 and 61.9% (P < 0.0001), whereas the 3-year OS rates in group B were 54.7 and 92.2% (P < 0.01), respectively. Multivariate analysis using the proportional hazards model revealed that sFas most significantly correlated with overall survival (P < 0.05).

Conclusion

Serum sFas is thus a useful tool for selecting the appropriate therapeutic strategy for DLBCL.

Keywords

Diffuse large B-cell lymphoma (DLBCL) Soluble Fas (sFas) Prognostic analysis Revised International Prognostic Index 

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Takeshi Hara
    • 1
  • Hisashi Tsurumi
    • 1
  • Naoe Goto
    • 1
  • Nobuhiro Kanemura
    • 1
  • Takeshi Yoshikawa
    • 2
  • Senji Kasahara
    • 1
  • Toshiki Yamada
    • 1
  • Michio Sawada
    • 3
  • Hideko Goto
    • 4
  • Kenji Fukuno
    • 3
  • Jun-ichi Kitagawa
    • 1
  • Ichiro Yasuda
    • 1
  • Naoki Katsumura
    • 1
  • Masao Takemura
    • 5
  • Takeshi Takahashi
    • 2
  • Tsuyoshi Takami
    • 6
  • Hisataka Moriwaki
    • 1
  1. 1.First Department of Internal MedicineGifu University Graduate School of MedicineGifuJapan
  2. 2.Division of HematologyGifu Municipal HospitalGifuJapan
  3. 3.Department of HematologyGifu Red-Cross HospitalGifuJapan
  4. 4.Department of Internal MedicineKisogawa Municipal HospitalIchinomiyaJapan
  5. 5.Department of Informative Clinical MedicineGifu University Graduate School of MedicineGifuJapan
  6. 6.Department of ImmunopathologyGifu University Graduate School of MedicineGifuJapan

Personalised recommendations